Last reviewed · How we verify
NCT06216808
A First-in-human Study of HyperQureTM", Laparoscopic Renal Denervation Therapy in Patient With Resistant Hypertension
NA trial testing HyperQure Renal Denervation System in Resistant Hypertension in 10 participants. Currently enrolling.
6 March 2026
Quick facts
| Lead sponsor | DeepQure Inc. |
|---|---|
| Phase | NA |
| Status | Recruiting now |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | device feasibility |
| Enrollment | 10 |
| Start date | 4 December 2023 |
| Primary completion | 6 March 2026 |
| Estimated completion | 4 December 2026 |
| Sites | 7 locations across South Korea |
Drugs / interventions tested
- HyperQure Renal Denervation System
Conditions studied
- Resistant Hypertension — all drugs for Resistant Hypertension →
Sponsor
DeepQure Inc.
Who can join
Adults 19 to 79, any sex, with Resistant Hypertension. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
HQ-HTN-K01-02 is a prospective, multicenter, single arm, open label, first-in-human study to evaluate the safety and initial efficacy of HyperQureTM, laparoscopic denervation therapy, in patients with resistant hypertension on 3 or more antihypertensive medications
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Resistant Hypertension Treated With Extravascular Renal Denervation.
Park H, Hwang EC, Jo JK, Shin JH, et al · · 2025 · PMID 40713111 · DOI 10.1016/j.jaccas.2025.104126
Verify or expand the search:
- PubMed search for NCT06216808
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Resistant Hypertension
Currently open trials in the same condition.
- NCT07383220 — Effect of Electrical Stimulation and Exercise on Blood Flow in Patients With Resistant High Blood Pressure · NA · recruiting
- NCT07081243 — Symplicity China Study · recruiting
- NCT07207226 — Arterial Stiffness as a Tool to Investigate Adherence in Resistant Hypertension · NA · recruiting
- NCT06526858 — Early Feasibility Study of "HyperQureTM RDN System", Laparoscopic Renal Denervation Therapy, in Patients With Resistant · NA · recruiting
- NCT05888233 — Allopurinol Improves Heart Function in African Americans With Resistant Hypertension · Phase 2 · recruiting
Other DeepQure Inc. trials
Trials by the same sponsor.
- NCT06526858 — Early Feasibility Study of "HyperQureTM RDN System", Laparoscopic Renal Denervation Therapy, in Patients With Resistant · NA · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06216808 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by DeepQure Inc.
- Last refreshed: 4 December 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06216808.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing